PARTNER/PARTNERING: BRCA Positive and Triple Negative Breast Cancer Phase II Poor Responders Sub-Study to Establish if Post-Neoadjuvant, Pre-Surgical Addition of Novel Therapies Improves Pathological Outcome at Surgery